558 related articles for article (PubMed ID: 33985863)
1. Opioid use disorder treatment for people experiencing homelessness: A scoping review.
McLaughlin MF; Li R; Carrero ND; Bain PA; Chatterjee A
Drug Alcohol Depend; 2021 Jul; 224():108717. PubMed ID: 33985863
[TBL] [Abstract][Full Text] [Related]
2. National trends in substance use treatment admissions for opioid use disorder among adults experiencing homelessness.
Han BH; Doran KM; Krawczyk N
J Subst Abuse Treat; 2022 Jan; 132():108504. PubMed ID: 34102461
[TBL] [Abstract][Full Text] [Related]
3. "Sick and tired of being sick and tired": Exploring initiation of medications for opioid use disorder among people experiencing homelessness.
Swartz N; Adnan T; Peréa F; Baggett TP; Chatterjee A
J Subst Abuse Treat; 2022 Jul; 138():108752. PubMed ID: 35277306
[TBL] [Abstract][Full Text] [Related]
4. The impact of methamphetamine/amphetamine use on receipt and outcomes of medications for opioid use disorder: a systematic review.
Frost MC; Lampert H; Tsui JI; Iles-Shih MD; Williams EC
Addict Sci Clin Pract; 2021 Oct; 16(1):62. PubMed ID: 34635170
[TBL] [Abstract][Full Text] [Related]
5. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
[TBL] [Abstract][Full Text] [Related]
6. The case for a medication first approach to the treatment of opioid use disorder.
Winograd RP; Presnall N; Stringfellow E; Wood C; Horn P; Duello A; Green L; Rudder T
Am J Drug Alcohol Abuse; 2019; 45(4):333-340. PubMed ID: 31084515
[No Abstract] [Full Text] [Related]
7. Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco.
Carter J; Zevin B; Lum PJ
Addict Sci Clin Pract; 2019 May; 14(1):20. PubMed ID: 31060600
[TBL] [Abstract][Full Text] [Related]
8. Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial.
Molfenter T; Knudsen HK; Brown R; Jacobson N; Horst J; Van Etten M; Kim JS; Haram E; Collier E; Starr S; Toy A; Madden L
Implement Sci; 2017 Nov; 12(1):135. PubMed ID: 29141653
[TBL] [Abstract][Full Text] [Related]
9. Comorbid Health Conditions and Treatment Utilization among Individuals with Opioid Use Disorder Experiencing Homelessness.
Ali MM; Sutherland H; Rosenoff E
Subst Use Misuse; 2021; 56(4):571-574. PubMed ID: 33637031
[TBL] [Abstract][Full Text] [Related]
10. Medications for management of opioid use disorder.
Koehl JL; Zimmerman DE; Bridgeman PJ
Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
[TBL] [Abstract][Full Text] [Related]
11. COVID-19: A catalyst for change in telehealth service delivery for opioid use disorder management.
Mehtani NJ; Ristau JT; Snyder H; Surlyn C; Eveland J; Smith-Bernardin S; Knight KR
Subst Abus; 2021; 42(2):205-212. PubMed ID: 33684331
[TBL] [Abstract][Full Text] [Related]
12. Management of opioid withdrawal and initiation of medications for opioid use disorder in the hospital setting.
Carswell N; Angermaier G; Castaneda C; Delgado F
Hosp Pract (1995); 2022 Oct; 50(4):251-258. PubMed ID: 35837678
[TBL] [Abstract][Full Text] [Related]
13. Pain in People Experiencing Homelessness: A Scoping Review.
Anastas TM; Stewart JC; Rand KL; Hirsh AT
Ann Behav Med; 2023 Apr; 57(4):288-300. PubMed ID: 36745022
[TBL] [Abstract][Full Text] [Related]
14. Adherence to and Retention in Medications for Opioid Use Disorder Among Adolescents and Young Adults.
Viera A; Bromberg DJ; Whittaker S; Refsland BM; Stanojlović M; Nyhan K; Altice FL
Epidemiol Rev; 2020 Jan; 42(1):41-56. PubMed ID: 32239206
[TBL] [Abstract][Full Text] [Related]
15. Association of polysubstance use disorder with treatment quality among Medicaid beneficiaries with opioid use disorder.
Smart R; Kim JY; Kennedy S; Tang L; Allen L; Crane D; Mack A; Mohamoud S; Pauly N; Perez R; Donohue J
J Subst Abuse Treat; 2023 Jan; 144():108921. PubMed ID: 36327615
[TBL] [Abstract][Full Text] [Related]
16. Update on Barriers to Pharmacotherapy for Opioid Use Disorders.
Sharma A; Kelly SM; Mitchell SG; Gryczynski J; O'Grady KE; Schwartz RP
Curr Psychiatry Rep; 2017 Jun; 19(6):35. PubMed ID: 28526967
[TBL] [Abstract][Full Text] [Related]
17. Treatment for opioid use disorder in the Florida medicaid population: Using a cascade of care model to evaluate quality.
Johnson K; Hills H; Ma J; Brown CH; McGovern M
Am J Drug Alcohol Abuse; 2021 Mar; 47(2):220-228. PubMed ID: 33054435
[No Abstract] [Full Text] [Related]
18. Office-Based Addiction Treatment Retention and Mortality Among People Experiencing Homelessness.
Fine DR; Lewis E; Weinstock K; Wright J; Gaeta JM; Baggett TP
JAMA Netw Open; 2021 Mar; 4(3):e210477. PubMed ID: 33662132
[TBL] [Abstract][Full Text] [Related]
19. Access challenges to opioid use disorder treatment among individuals experiencing homelessness: Voices from the streets.
Hsu M; Jung OS; Kwan LT; Jegede O; Martin B; Malhotra A; Suzuki J
J Subst Use Addict Treat; 2024 Feb; 157():209216. PubMed ID: 37981243
[TBL] [Abstract][Full Text] [Related]
20. Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?
Nunes EV; Levin FR; Reilly MP; El-Bassel N
J Subst Abuse Treat; 2021 Mar; 122():108196. PubMed ID: 33221125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
